Clinical efficacy of arbekacin for Gram-negative bacteria
Yukihiro Hamada1, Kazuyoshi Tamura, Ikumi Koyama
1Department of Pharmacy, Kitasato East University Hospital, 2-1-1, Asamizodai, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan. yuki@kitasato-u.ac.jp
Abstract:
In an analysis of methicillin-resistant Staphylococcus aureus (MRSA) infected patients treated with arbekacin (ABK) only, Gram-negative bacteria (GNB) that were inhibited by low minimal inhibitory concentrations (MICs) of amikacin (AMK) or gentamycin (GM) were eradicated by the end of the ABK treatment. On the other hand, GNB that were only inhibited by high MICs of AMK or GM persisted until the end of treatment with ABK only. Thus, ABK can be expected to be effective even in cases of mixed infection with GNB and MRSA.
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis

